Ginkgo Bioworks Holdings Inc (DNA) has a current Price-to-Book (P/B) ratio of 0.88. Compared to its 3-year average P/B ratio of 1.44, the current P/B ratio is approximately -38.71% higher. Relative to its 5-year average P/B ratio of 3.17, the current P/B ratio is about -72.18% higher. Ginkgo Bioworks Holdings Inc (DNA) has a Forward Free Cash Flow (FCF) yield of approximately -37.86%. Compared to its 3-year average FCF yield of -40.06%, the current FCF yield is approximately -5.50% lower. Relative to its 5-year average FCF yield of -26.80%, the current FCF yield is about 41.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for DNA competitors is 1.43, providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA.N) exhibits a P/S ratio of 2.78, which is 94.73% above the industry average. Given its robust revenue growth of -56.39%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of DNA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of DNA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is DNA currently overvalued or undervalued?

What is Ginkgo Bioworks Holdings Inc (DNA) fair value?

DNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ginkgo Bioworks Holdings Inc (DNA) is between 5.21 to 8.37 according to relative valuation method.

How does DNA's valuation metrics compare to the industry average?

The average P/S ratio for DNA's competitors is 1.43, providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA) exhibits a P/S ratio of 2.78, which is 94.73% above the industry average. Given its robust revenue growth of -56.39%, this premium appears unsustainable.

What is the current P/B ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Mar 02 2026?

As of Mar 02 2026, Ginkgo Bioworks Holdings Inc (DNA) has a P/B ratio of 0.88. This indicates that the market values DNA at 0.88 times its book value.

What is the current FCF Yield for Ginkgo Bioworks Holdings Inc (DNA) as of Mar 02 2026?

As of Mar 02 2026, Ginkgo Bioworks Holdings Inc (DNA) has a FCF Yield of -37.86%. This means that for every dollar of Ginkgo Bioworks Holdings Inc's market capitalization, the company generates -37.86 cents in free cash flow.

What is the current Forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Mar 02 2026?

As of Mar 02 2026, Ginkgo Bioworks Holdings Inc (DNA) has a Forward P/E ratio of -1.88. This means the market is willing to pay $-1.88 for every dollar of Ginkgo Bioworks Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Mar 02 2026?

As of Mar 02 2026, Ginkgo Bioworks Holdings Inc (DNA) has a Forward P/S ratio of 2.78. This means the market is valuing DNA at $2.78 for every dollar of expected revenue over the next 12 months.

DNA Valuation